Biggest changeThe following table sets forth our results of operations for the periods indicated: Year Ended December 31, 2023 2022 2023 2022 (In thousands) (As a percentage of revenue) Product sales $ 53,123 $ 55,032 83 % 92 % Licensing, royalty, patent, and other revenue 10,642 4,953 17 8 Total revenue 63,765 59,985 100 100 Cost of product sales 24,693 25,112 39 42 Cost of licensing, royalty, patent, and other revenue 1,827 928 3 2 Total cost of sales 26,520 26,040 42 43 Gross profit 37,245 33,945 58 57 Operating expenses: Research and development 11,776 11,108 19 19 General and administrative 14,296 11,741 22 20 Sales and marketing 5,288 4,869 8 8 Total operating expenses 31,360 27,718 49 47 Income from operations 5,885 6,227 9 10 Interest expense (63) (274) — — Other income, net 3,214 190 5 — Net income before income taxes 9,036 6,143 14 10 Income tax benefit (expense) 16 (14) — — Net income and comprehensive income $ 9,052 $ 6,129 14 % 10 % Comparison of the Years Ended December 31, 2023 and 2022 Revenue We generated 78% and 85% of our revenue from products sold through distributors for the years ended December 31, 2023 and 2022, respectively.
Biggest changeThe following table sets forth our results of operations for the periods indicated: Year Ended December 31, 2024 2023 2024 2023 (In thousands) (As a percentage of revenue) Product sales $ 42,203 $ 53,123 84 % 83 % Licensing, royalty, patent, and other revenue 8,199 10,642 16 17 Total revenue 50,402 63,765 100 100 Cost of product sales 22,812 24,693 45 39 Cost of licensing, royalty, patent, and other revenue 1,464 1,827 3 3 Total cost of sales 24,276 26,520 48 42 Gross profit 26,126 37,245 52 58 Operating expenses: Research and development 13,686 11,776 27 19 General and administrative 14,141 14,296 28 22 Sales and marketing 5,390 5,288 11 8 Total operating expenses 33,217 31,360 66 49 (Loss) income from operations (7,091) 5,885 (14) 9 Interest expense — (63) — — Other income, net 7,832 3,214 16 5 Net income before income taxes 741 9,036 2 14 Income tax benefit 40 16 — — Net income $ 781 $ 9,052 2 % 14 % Comparison of the Years Ended December 31, 2024 and 2023 Revenue We generated 79% and 78% of our revenue from products sold through distributors for the years ended December 31, 2024 and 2023, respectively. 28 Table of Contents We maintain a direct selling relationship, for strategic purposes, with several key customer accounts.
We record inventory write-downs for the valuation of inventory when required based on our analyses and any write-downs result in a new cost basis for the affected item. Recent Accounting Pronouncements See Note 2 in the accompanying Notes to Financial Statements in Part II, Item 8 of this Form 10-K for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations.
We record inventory write-downs for the valuation of inventory when required based on our analyses and any write-downs result in a new cost basis for the affected item. Recent Accounting Pronouncements See Note 2 in the accompanying Notes to Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations.
Accordingly, we determined the 37 Table of Contents licenses were not distinct within the context of the contract and combined the license with other performance obligations. As a result, we are recognizing revenue related to the performance obligations over time using the input method based on costs incurred to date relative to the total expected costs of the contract over the performance obligation period. Inventory We record inventories at the lower of cost, determined on a first-in, first-out basis or net realizable value.
Accordingly, we determined the licenses were not distinct within the context of the contract and combined the license with other performance obligations. As a result, we are recognizing revenue related to the performance obligations over time using the input method based on costs incurred to date relative to the total expected costs of the contract over the performance obligation period. 33 Table of Contents Inventory We record inventories at the lower of cost, determined on a first-in, first-out basis or net realizable value.
The licenses provided to the customer are not transferable, are of limited value without the promised development services, and the customer cannot benefit from the license agreements without the specific obligated services in the development subcontract, as there is strong interdependency between the licenses and the development subcontract.
The licenses provided to the customer are not transferable, are of limited value without the promised development services, and the customer cannot benefit from the license agreements without the specific obligated services in the development subcontract, as there is strong interdependence between the licenses and the development subcontract.
See “Risk Factors” in Part II, Item 1A of this report for additional risks we face due to COVID-19. Results of Operations Below are factors we want to highlight for understanding our 2023 annual results and year over year comparison with proper historical perspective: ● The first half of 2023 was impacted by supply chain challenges that were overcome in the second half of the year as the industry reverted to pre-COVID-19 seasonal patterns. ● Our commitment to improving our manufacturing excellence enabled us to drive yield improvements within our internal and external foundries network to sustain and improve existing product margins.
See “Risk Factors” in Part I, Item 1A of this report for additional risks we face due to health-related events. Results of Operations Below are factors we want to highlight for understanding our 2024 annual results and year-over-year comparison with proper historical perspective: ● The first half of 2024 was impacted by supply chain challenges that were overcome in the second half of the year as the industry reverted to pre-health-related outbreak seasonal patterns. ● Our commitment to improving our manufacturing excellence enabled us to drive yield improvements within our internal and external foundries network to sustain and improve existing product margins.
Liquidity and Capital Resources As of December 31, 2023, we had $36.9 million of cash and cash equivalents, compared to $26.8 million as of December 31, 2022. As of December 31, 2023, we have no outstanding debt as we paid off our 2019 Credit Facility in full in March 2023.
Liquidity and Capital Resources As of December 31, 2024, we had $42.1 million of cash and cash equivalents, compared to $36.9 million as of December 31, 2023. As of December 31, 2024, we have no outstanding debt as we paid off our 2019 Credit Facility in full in March 2023.
The change in our net operating assets and liabilities was primarily due to an increase in accounts receivable of $0.9 million due to timing of cash receipts for outstanding balances, an increase in inventory of $1.7 million to meet anticipated production volumes, an increase in prepaid and other current assets of $0.4 million, an increase in other assets of $0.2 million, an increase in accounts payable of $0.5 million, an increase in accrued liabilities of $0.8 million, and a decrease in deferred revenue of $0.5 million.
The change in our net operating assets and liabilities was primarily due to an increase in contract obligations of $2.0 million due to contracts the Company entered into in the third quarter of 2024, an increase in accounts receivable of $0.2 million due to timing of cash receipts for outstanding balances, an increase in inventory of $0.7 million to meet anticipated production volumes, an increase in prepaid and other current assets of $0.3 million, an increase in other assets of $0.5 million, a decrease in accounts payable of $0.4 million, a decrease in accrued liabilities of $1.9 million, and a decrease in deferred revenue of $0.3 million.
The following table presents a reconciliation of net income, the most directly comparable GAAP measure, to Adjusted EBITDA for the periods indicated: Year Ended December 31, 2023 2022 Adjusted EBITDA reconciliation: Net income $ 9,052 $ 6,129 Depreciation and amortization 1,205 982 Stock-based compensation expense 5,005 4,408 Interest expense 63 274 Income tax (benefit) expense (16) 14 Adjusted EBITDA $ 15,309 $ 11,807 Our Adjusted EBITDA for the year ended December 31, 2023 includes a one-time employee retention tax credit received of $2.0 million in the second quarter of 2023.
The following table presents a reconciliation of net income, the most directly comparable GAAP measure, to Adjusted EBITDA for the periods indicated: Year Ended December 31, 2024 2023 (in thousands) Adjusted EBITDA reconciliation: Net income $ 781 $ 9,052 Depreciation and amortization 1,731 1,205 Stock-based compensation expense 6,713 5,005 Interest expense — 63 Income tax benefit (40) (16) Adjusted EBITDA $ 9,185 $ 15,309 Our Adjusted EBITDA for the year ended December 31, 2023 includes a one-time employee retention tax credit received of $2.0 million in the second quarter of 2023.
Cash Flows The following table summarizes our cash flows for the periods indicated (in thousands): Year Ended December 31, 2023 2022 (In thousands) Cash provided by operating activities $ 13,128 $ 9,493 Cash used in investing activities (1,385) (2,586) Cash used in financing activities (1,592) (1,521) Cash Flows From Operating Activities During the year ended December 31, 2023, cash provided by operating activities was $13.1 million, which consisted of net income of $9.1 million, non-cash charges of $6.4 million and changes in net operating assets and liabilities of $2.3 million.
Cash Flows The following table summarizes our cash flows for the periods indicated (in thousands): Year Ended December 31, 2024 2023 (In thousands) Cash provided by operating activities $ 7,099 $ 13,128 Cash used in investing activities (3,060) (1,385) Cash provided by (used in) financing activities 1,112 (1,592) Cash Flows from Operating Activities During the year ended December 31, 2024, cash provided by operating activities was $7.1 million, which consisted of net income of $0.8 million, non-cash charges of $8.4 million and changes in net operating assets and liabilities of $2.1 million.
Price protection rights grant distributors the right to a credit in the event of declines in the price of our products. Under these circumstances, we remit back to the distributor a portion of their original purchase price after the resale transaction is completed in the form of a credit against the distributors’ outstanding accounts receivable balance.
Under these circumstances, we remit back to the distributor a portion of their original purchase price after the resale transaction is completed in the form of a credit against the distributors’ outstanding accounts receivable balance.
Sales and marketing expenses increased by $0.4 million, or 8.6%, from $4.9 million during the year ended December 31, 2022, to $5.3 million during the year ended December 31, 2023. The increase was primarily due to an increase in variable compensation costs and contract labor.
Sales and marketing expenses increased by $0.1 million, or 1.9%, from $5.3 million during the year ended December 31, 2023, to $5.4 million during the year ended December 31, 2024. The change was primarily due to an increase in headcount and contract labor, partially offset by lower variable compensation costs.
Personnel-related expenses, including salaries, benefits, bonuses, and stock-based compensation, are among the most significant component of each of our operating expense categories. Year Ended December 31, Change 2023 2022 Amount % (Dollars in thousands) Research and development $ 11,776 $ 11,108 $ 668 6.0 % Research and development as a % of revenue 19 % 19 % Research and Development Expenses.
Personnel-related expenses, including salaries, benefits, bonuses, and stock-based compensation, are among the most significant component of each of our operating expense categories. Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Research and development $ 13,686 $ 11,776 $ 1,910 16.2 % Research and development as a % of revenue 27 % 19 % Research and Development Expenses .
Research and development expenses increased by $0.7 million, or 6.0%, from $11.1 million during the year ended December 31, 2022, to $11.8 million during the year ended December 31, 2023.
Research and development expenses increased by $1.9 million, or 16.2%, from $11.8 million during the year ended December 31, 2023, to $13.7 million during the year ended December 31, 2024.
During the year ended December 31, 2022, cash used in investing activities was $2.6 million, which consisted of capital expenditures primarily for the purchase of manufacturing equipment and purchased software offset by a nominal amount in proceeds received on the sale of property and equipment. Cash Flows From Financing Activities During the year ended December 31, 2023, cash used in financing activities was $1.6 million, which primarily consisted of $2.8 million of payments to pay off our 2019 Credit Facility offset by $1.2 million in proceeds from stock option exercises and purchases of shares under our employee stock purchase plan.
During the year ended December 31, 2023, cash used in financing activities was $1.6 million, which primarily consisted of $2.8 million of payments to pay off our 2019 Credit Facility offset by $1.2 million in proceeds from stock option exercises and purchases of shares under our employee stock purchase plan.
Interest Expense Year Ended December 31, Change 2023 2022 Amount % (Dollars in thousands) Interest expense $ 63 $ 274 $ (211) (77.0) % Interest expense decreased by $0.2 million, or 77.0%, from $0.3 million during the year ended December 31, 2022, to $0.1 million during the year ended December 31, 2023.
Interest Expense Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Interest expense $ — $ 63 $ (63) (100.0) % Interest expense decreased by $0.1 million, or 100.0%, from $0.1 million during the year ended December 31, 2023, to zero during the year ended December 31, 2024.
The decrease was due to having no outstanding balance under our 2019 Credit Facility as we paid off the outstanding balance in full in March 2023, resulting in no interest incurred during the remainder of 2023 after the outstanding balance was paid in full. 33 Table of Contents Other Income, Net Year Ended December 31, Change 2023 2022 Amount % (Dollars in thousands) Other income, net $ 3,214 $ 190 $ 3,024 1,591.6 % Other income, net changed by $3.0 million, from $0.2 million of expense during the year ended December 31, 2022, to $3.2 million of income during the year ended December 31, 2023.
The change was due to having no outstanding balance under our 2019 Credit Facility as we paid off the outstanding balance in full in March 2023, resulting in no interest incurred during 2024 after the outstanding balance was paid in full. 30 Table of Contents Other Income, Net Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Other income, net $ 7,832 $ 3,214 $ 4,618 143.7 % Other income, net increased by $4.6 million, from $3.2 million during the year ended December 31, 2023, to $7.8 million during the year ended December 31, 2024.
During the year ended December 31, 2022, cash provided by operating activities was $9.5 million, which primarily consisted of net income of $6.1 million, adjusted by non-cash charges of $5.3 million and a decrease of $1.9 million in our net operating assets and liabilities.
During the year ended December 31, 2023, cash provided by operating activities was $13.1 million, which consisted of net income of $9.1 million , non-cash charges of $6.4 million and changes in net operating assets and liabilities of $2.3 million.
We recognize sales of products in discrete unit form at a point in time, revenue related to licensing agreements when we have delivered control of the technology, revenue related to royalty agreements in the period in which sales generated from products sold using our technology occurs, sales of backend foundry services over time, and design services to third parties either at a point in time or over time, depending on the nature of the services. 36 Table of Contents Product Revenue For products sold in their discrete form, we either sell our products directly to OEMs, ODMs, contract manufacturers (CMs), or through a network of distributors, who in turn sell to those customers.
We recognize sales of products in discrete unit form at a point in time, revenue related to licensing agreements when we have delivered control of the technology, revenue related to royalty agreements in the period in which sales generated from products sold using our technology occurs, sales of backend foundry services over time, and design services to third parties either at a point in time or over time, depending on the nature of the services.
The decrease was primarily due to a reduction in product sales compared to the prior year. Cost of licensing, royalty, patent, and other revenue increased by $0.9 million, or 96.9%, from $0.9 million during the year ended December 31, 2022, to $1.8 million during the year ended December 31, 2023.
The change was primarily due to a reduction in product sales compared to the prior year, offset in part by increased yields on our toggle products. Cost of licensing, royalty, patent, and other revenue decreased by $0.4 million, or 19.9%, from $1.8 million during the year ended December 31, 2023, to $1.5 million during the year ended December 31, 2024.
The increase was due to an increase in licensing costs related to labor and materials associated with the progression of our RAD-Hard projects. 32 Table of Contents Our gross margin increased from 56.6% during the year ended December 31, 2022, to 58.4% during the year ended December 31, 2023.
The change was due to a decrease in licensing costs related to labor and materials associated with the progression of our RAD-Hard projects. Our gross margin decreased from 58.4% during the year ended December 31, 2023, to 51.8% during the year ended December 31, 2024.
Cost of Sales and Gross Margin Year Ended December 31, Change 2023 2022 Amount % (Dollars in thousands) Cost of sales $ 24,693 $ 25,112 $ (419) (1.7) % Cost of licensing, royalty, patent, and other revenue 1,827 928 899 96.9 % Total cost of sales $ 26,520 $ 26,040 $ 480 1.8 % Gross margin 58.4 % 56.6 % * * Cost of product sales decreased by $0.4 million, or 1.7%, from $25.1 million during the year ended December 31, 2022, to $24.7 million during the year ended December 31, 2023.
Cost of Sales and Gross Margin Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Cost of sales $ 22,812 $ 24,693 $ (1,881) (7.6) % Cost of licensing, royalty, patent, and other revenue 1,464 1,827 (363) (19.9) % Total cost of sales $ 24,276 $ 26,520 $ (2,244) (8.5) % Gross margin 51.8 % 58.4 % * * Cost of product sales decreased by $1.9 million, or 7.6%, from $24.7 million during the year ended December 31, 2023, to $22.8 million during the year ended December 31, 2024.
These were offset by an increase of $0.6 million in accounts payable due to timing of invoice due dates and a $0.2 million increase in lease liabilities. 34 Table of Contents Cash Flows From Investing Activities During the year ended December 31, 2023, cash used in investing activities was $1.4 million, which consisted of capital expenditures primarily for the purchase of manufacturing equipment offset by a nominal amount in proceeds received on the sale of property and equipment.
During the year ended December 31, 2023, cash used in investing activities was $1.4 million, which consisted of capital expenditures primarily for the purchase of manufacturing equipment offset by a nominal amount in proceeds received on the sale of property and equipment.
General and administrative expenses increased by $2.6 million, or 21.8%, from $11.7 million during the year ended December 31, 2022, to $14.3 million during the year ended December 31, 2023.
General and administrative expenses decreased by $0.2 million, or 1.1%, from $14.3 million during the year ended December 31, 2023, to $14.1 million during the year ended December 31, 2024.
For sales directly to OEMs, ODMs and CMs, we recognize revenue when the OEM, ODM or CM obtains control of the product, which occurs at a point in time, generally upon shipment to the customer.
For sales directly to OEMs, ODMs and CMs, we recognize revenue when the OEM, ODM or CM obtains control of the product, which occurs at a point in time, generally upon shipment to the customer. 32 Table of Contents From time to time, we may provide distributors with price adjustments subsequent to the delivery of product to them and such amounts are dependent on the end customer and product sales price.
During the year ended December 31, 2022, cash used in financing activities was $1.5 million, which primarily consisted of $2.4 million in payments on long-term debt offset by $0.9 million in proceeds from stock option exercises and purchases of shares under our employee stock purchase plan.
Cash Flows from Financing Activities During the year ended December 31, 2024, cash provided by financing activities was $1.1 million, which consisted of proceeds from stock option exercises and purchases of shares under our employee stock purchase plan.
The increase was primarily due to the employee retention tax credit received during the second quarter of 2023 of $2.0 million, along with an increase in interest income earned on the money market cash account as a result of increased cash balances and increasing interest rates, offset by a loss on prepayment and termination of our 2019 Credit Facility.
The change was primarily due to other income of $6.1 million recognized from a strategic award received by the Company to develop a long-term plan to provide manufacturing services for aerospace and defense segments, a change in interest income earned on the money market cash account as a result of a change in cash balances, along with the non-recurrence of a loss on prepayment and termination of our 2019 Credit Facility, offset by non-recurrence of the employee retention tax credit of $2.0 million received during the second quarter of 2023.
Our gross margin increased by offsetting increased pricing from suppliers with increased yields on our toggle products and increased licensing revenue to offset the decrease in product sales. Operating Expenses Our operating expenses consist of research and development, general and administrative and sales and marketing expenses.
Our gross margin decreased as a result of a shift in product mix, a decrease in FAB loadings, and a decrease in licensing revenue partially offset by increased yields on our toggle products. 29 Table of Contents Operating Expenses Our operating expenses consist of research and development, general and administrative and sales and marketing expenses.
Our revenue by region for the periods indicated was as follows (in thousands): Year Ended December 31, 2023 2022 APAC $ 33,096 $ 35,631 North America 15,922 14,533 EMEA 14,747 9,821 Total revenue $ 63,765 $ 59,985 Year Ended December 31, Change 2023 2022 Amount % (Dollars in thousands) Product sales $ 53,123 $ 55,032 $ (1,909) (3.5) % Licensing, royalty, patent, and other revenue 10,642 4,953 5,689 114.9 % Total revenue $ 63,765 $ 59,985 $ 3,780 6.3 % Total revenue increased by $3.8 million, or 6.3%, from $60.0 million during the year ended December 31, 2022, to $63.8 million during the year ended December 31, 2023.
Our revenue by region for the periods indicated was as follows (in thousands): Year Ended December 31, 2024 2023 APAC $ 28,688 $ 33,096 North America 10,710 15,922 EMEA 11,004 14,747 Total revenue $ 50,402 $ 63,765 Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Product sales $ 42,203 $ 53,123 $ (10,920) (20.6) % Licensing, royalty, patent, and other revenue 8,199 10,642 (2,443) (23.0) % Total revenue $ 50,402 $ 63,765 $ (13,363) (21.0) % Total revenue decreased by $13.4 million, or 21.0%, from $63.8 million during the year ended December 31, 2023, to $50.4 million during the year ended December 31, 2024.
We recognize revenue by geography based on the region in which our products are sold, and not to where the end products in which they are assembled are shipped.
We have organized our sales team and representatives into three primary regions: Asia-Pacific (APAC); North America; and Europe, Middle East and Africa (EMEA). We recognize revenue by geography based on the region in which our products are sold, and not to where the end products in which they are assembled are shipped.
The increase was primarily due to higher expenses relating to the development and enhancement of our new xSPI family of STT-MRAM products and increases in share-based compensation. Year Ended December 31, Change 2023 2022 Amount % (Dollars in thousands) General and administrative $ 14,296 $ 11,741 $ 2,555 21.8 % General and administrative as a % of revenue 22 % 20 % General and Administrative Expenses.
The change was primarily due to the development and enhancement of our new Extended Serial Peripheral Interface (xSPI) family of STT-MRAM products, which offer high-performance, multiple I/O, SPI-compatibility and feature a high-speed, low pin count SPI compatible interface, and increases in share-based compensation. Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) General and administrative $ 14,141 $ 14,296 $ (155) (1.1) % General and administrative as a % of revenue 28 % 22 % General and Administrative Expenses.
Licensing, royalty, patent, and other revenue is a highly variable revenue item characterized by a small number of transactions annually with revenue based on size and terms of each transaction. We estimate royalty revenue earned throughout the year, with an annual adjustment recognized for actual sales in the first quarter of each fiscal year.
The decrease was primarily due to a decrease in product sales of $10.9 million due to timing of customer demand. Licensing, royalty, patent, and other revenue is a highly variable revenue item characterized by a small number of transactions annually with revenue based on size and terms of each transaction.
The increase was primarily due to increases in professional service costs, share-based compensation, and depreciation. Year Ended December 31, Change 2023 2022 Amount % (Dollars in thousands) Sales and marketing $ 5,288 $ 4,869 $ 419 8.6 % Sales and marketing as a % of revenue 8 % 8 % Sales and Marketing Expenses.
The change was primarily driven by a reduction in professional services. Year Ended December 31, Change 2024 2023 Amount % (Dollars in thousands) Sales and marketing $ 5,390 $ 5,288 $ 102 1.9 % Sales and marketing as a % of revenue 11 % 8 % Sales and Marketing Expenses.
The non-cash charges primarily consisted of stock-based compensation of $4.4 million, depreciation and amortization of $1.0 million, and non-cash interest expense of $0.1 million, offset by a gain on disposal of property and equipment of $0.2 million.
The non-cash charges primarily consisted of stock-based compensation of $6.7 million and depreciation and amortization of $1.7 million.
The increase was primarily due to an increase in licensing revenues of $5.5 million from our contractual agreements with customers for the development of RAD-Hard products, along with an increase of $0.7 million of other revenue related to a contractual arrangement with a customer for the development of reliability models for strategic radiation hardened toggle MRAM, offset in part by a decrease of $0.5 million in royalty revenue.
The decrease was primarily due to the progression of our contractual agreements with customers for the development of RAD-Hard products, along with the conclusion of a contractual arrangement with a customer for the development of reliability models for strategic radiation hardened toggle MRAM. There were no patent sales during the year ended December 31, 2024.
From time to time, we may provide distributors with price adjustments subsequent to the delivery of product to them and such amounts are dependent on the end customer and product sales price. Price adjustments can be based on a variety of factors, including customer, product, quantity, geography, and competitive differentiation.
Price adjustments can be based on a variety of factors, including customer, product, quantity, geography, and competitive differentiation. Price protection rights grant distributors the right to a credit in the event of declines in the price of our products.
For additional information about the 2019 Credit Facility, see Note 6 in the accompanying Notes to Financial Statements in Part II, Item 8 of this Form 10-K. Critical Accounting Policies and Significant Judgements and Estimates Our financial statements have been prepared in accordance with U.S. GAAP.
Critical Accounting Policies and Significant Judgements and Estimates Our financial statements have been prepared in accordance with U.S. GAAP.
The change in our net operating assets and liabilities was primarily due to an increase of $2.5 million in accounts receivable due to an increased sales volume and timing of cash receipts for outstanding balances and a $0.3 million increase in inventory.
The change in our net operating assets and liabilities was primarily due to an increase in accounts receivable of $0.9 million due to timing of cash receipts for outstanding balances, an increase in inventory of $1.7 million to meet anticipated production volumes, an increase in prepaid and other current assets of $0.4 million, an 31 Table of Contents increase in other assets of $0.2 million, an increase in accounts payable of $0.5 million, an increase in accrued liabilities of $0.8 million, and a decrease in deferred revenue of $0.5 million. Cash Flows from Investing Activities During the year ended December 31, 2024, cash used in investing activities was $3.1 million, which consisted of capital expenditures primarily for the purchase of manufacturing equipment and purchased software.
These actions may include further altering our operations in order to protect the best interests of our employees, customers and suppliers, and to comply with government requirements, while also planning and executing our business to best support our customers, suppliers, and partners. The ultimate extent of the impact of COVID-19 on our business, results of operations and financial condition will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted.
These crises and outbreaks can adversely affect global economies and financial markets, which have the potential to negatively impact our operations and financial condition. The ultimate extent of the impact of health-related events on our business, results of operations and financial condition will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted.
Licensing, royalty, patent, and other revenue increased by $5.7 million, from $5.0 million during the year ended December 31, 2022, to $10.6 million during the year ended December 31, 2023.
We estimate royalty revenue earned throughout the year, with an annual adjustment recognized for actual sales in the first quarter of each fiscal year. Licensing, royalty, patent, and other revenue decreased by $2.4 million, from $10.6 million during the year ended December 31, 2023, to $8.2 million during the year ended December 31, 2024.
New design wins in each successive quarter of 2023 were 66, 62, 37, and 52, respectively, compared to 61, 49, 48, and 52 in each successive quarter of 2022, respectively. Effect of COVID-19 on our Business The COVID-19 outbreak resulted in government authorities around the world implementing numerous measures to try to reduce the spread of COVID-19.
New design wins in each successive quarter of 2024 were 31, 44, 50, and 53, respectively, compared to 66, 62, 37, and 52 in each successive quarter of 2023, respectively. 27 Table of Contents Effect of Health-Related Outbreaks on Our Business Our global operations expose us to risks arising from public health crises and health-related outbreaks.